William Blair Reaffirms Outperform Rating for Stevanato Group (NYSE:STVN)

William Blair reaffirmed their outperform rating on shares of Stevanato Group (NYSE:STVN) in a research report released on Friday morning,RTT News reports. William Blair also issued estimates for Stevanato Group’s Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $0.23 EPS.

Several other equities research analysts have also recently issued reports on STVN. Morgan Stanley reiterated an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. UBS Group cut their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday. Wolfe Research initiated coverage on Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of €27.75 ($30.16).

Stevanato Group Trading Up 4.9 %

Shares of NYSE:STVN opened at €21.72 ($23.61) on Friday. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The stock has a market cap of $6.58 billion, a PE ratio of 46.21, a P/E/G ratio of 7.18 and a beta of 0.60. The business has a 50 day moving average of €21.38 and a 200-day moving average of €20.55. Stevanato Group has a 12-month low of €16.56 ($18.00) and a 12-month high of €33.49 ($36.40).

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.22). The business had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. As a group, equities research analysts forecast that Stevanato Group will post 0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of STVN. Zions Bancorporation N.A. acquired a new stake in Stevanato Group in the third quarter valued at $1,049,000. Sivik Global Healthcare LLC bought a new position in shares of Stevanato Group during the 3rd quarter worth about $2,800,000. King Wealth Management Group boosted its position in shares of Stevanato Group by 30.2% during the 3rd quarter. King Wealth Management Group now owns 94,800 shares of the company’s stock worth $1,896,000 after purchasing an additional 22,000 shares in the last quarter. Royce & Associates LP boosted its position in shares of Stevanato Group by 45.8% during the 3rd quarter. Royce & Associates LP now owns 343,159 shares of the company’s stock worth $6,863,000 after purchasing an additional 107,869 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock valued at $1,027,000 after acquiring an additional 8,669 shares in the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.